Integrated Symposium at ECCMID 2023
Tuesday, 18 April 2023
Registration and Breakfast
08:30 – 09:00
Symposium and Panel Discussion
09:00 – 10:00
You must be registered for ECCMID 2023 in order to attend this Integrated Symposium
Bella Center Copenhagen
Hall F
Center Boulevard 5
DK - 2300 Copenhagen
Also Available to Virtual Attendees via Online Simulcast
FACULTY
Roy F. Chemaly, MD, MPH, FACP, FIDSA, CMQ
(ESCMID-appointed Chair)
Professor, Medicine
Department of ID/IC/EH
Chief Infection Control Officer
Director, Clinical Virology Research Program
UT MD Anderson Cancer Center
Houston, TX, United States
Genovefa Papanicolaou, MD
(Organiser-appointed Chair)
Infectious Disease Service
Memorial Sloan Kettering Cancer Center
Professor, Medicine
Weill Cornell Medical College
Cornell University
New York, NY, United States
Hans H. Hirsch, MD, MSc
Professor, Senior Clinical Consultant
Transplantation & Clinical Virology
University of Basel
Basel, Switzerland
Atul Humar, MD, FRCPC, FAST
Professor, Department of Medicine
University of Toronto
R. Fraser Elliott Chair, Transplantation
University Health Network
Director, University of Toronto Transplant Institute
Toronto, ON, Canada
This symposium will help you improve your skills in managing cytomegalovirus (CMV) infection in transplant patients, including how to identify and treat refractory or drug-resistant CMV. Join our expert panel as they discuss CMV treatment guidelines after solid organ transplant (SOT) or hematopoietic cell transplant (HCT) and new therapy for refractory or drug-resistant CMV. Challenging real-world patient cases in CMV after transplantation will be presented, offering you an opportunity to test your clinical skills and learn from the experts. Do not miss it!
PROGRAM AGENDA
Genovefa Papanicolaou, MD and Roy F. Chemaly, MD, MPH, FACP, FIDSA, CMQ
Key Considerations for Treatment and Safety
Hans H. Hirsch, MD, MSc
What is the Role of New Therapies?
Atul Humar, MD, FRCPC, FAST
All Faculty
TARGET AUDIENCE
Infectious disease, transplantation, and internal medicine clinicians managing patients with CMV
EDUCATIONAL OBJECTIVES
Upon completion of this activity, participants should be better able to:
- Employ approved cytomegalovirus (CMV) prevention and antiviral treatment strategies in transplant patients based on safety and efficacy data
- Identify patients with refractory or resistant CMV using antiviral resistance testing
- Integrate key data on approved therapies for the selection of treatment for resistant or refractory CMV
PROVIDER STATEMENT
This educational activity was independently developed by RMEI Medical Education, LLC. All faculty and planner relevant financial relationships were identified and mitigated and RMEI Medical Education, LLC has reviewed the content and determined it to be fair, balanced, and without commercial bias.
SUPPORTER STATEMENT
Supported by an educational grant from Takeda.
FEE INFORMATION
There is no fee for this educational activity.
Disclosure of Financial Relationships
RMEI Medical Education, LLC (RMEI) requires instructors, planners, managers, and others in control of educational content to disclose all their financial relationships with ineligible companies over the previous 24 months. All identified financial relationships are thoroughly vetted and mitigated according to RMEI policy. RMEI will disclose to learners the presence or absence of relevant financial relationships for all persons in control of content before the learner engages in the education.
FOLLOW RMEI
Additional educational activities offered by RMEI Medical Education, LLC can be found
at www.RMEI.com or by calling toll-free (866) 770-RMEI.